Gilead Sciences Cayston Phase III trial meets co-primary endpoint
Patients receiving Cayston had an adjusted mean actual increase in FEV percent predicted from baseline over six months of 2.05% compared to a 0.66% decrease for patients receiving
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Piperacillin and tazobactam for injection is an antibacterial treatment indicated for use in adults with certain types of moderate to severe infections caused by piperacillin-resistant, piperacillin/tazobactam susceptible, ß-lactamase